Myriad and the mass media: The covering of a gene patent controversy

Genetics in Medicine

Volumn 9, Issue 12, 2007, Pages 850-855

  Caulfield, Timothy ^a   Bubela, Tania ^b   Murdoch, C J ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

BRCA; Breast cancer; Commercialization; Gene patents; Media; Myriad Genetics; Newspaper

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; LICENSING; MASS MEDIUM; PATENT; PUBLIC HEALTH SERVICE; STATISTICAL SIGNIFICANCE;

GENES, BRCA1; GENETIC SCREENING; HUMANS; INFORMATION DISSEMINATION; MASS MEDIA; NEWSPAPERS; PATENTS AS TOPIC; PUBLIC OPINION;

EID: 37349114113     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e31815bf965     Document Type: Article

References (20)

1. Caulfield T, Cook-Deegan B, Kieff S, Walsh J. Evidence and anecdotes: an analysis of human gene patenting controversies. Nat Biotechnol 2006;24:1091-1094.
2. Matthijs G. The European opposition against the BRCA gene patents. Fam Cancer 2006;5:95-102.
3. Eggertson L. Ontario defies US firm's genetic patent, continues cancer screening. CMAJ 2002;166:494.
4. Williams-Jones B. History of a gene patent: tracing the development and application of commercial BRCA testing. Health Law J 2002;10:123-146.
5. Ten Eyck T, Williment M. The national media and things genetic. Sci Commun 2003;25:129-152.
6. Marks L, Kalaitzandonakes N, Wilkins L, Zakharova L. Mass media framing of biotechnology news. Public Underst Sci 2007;16:183-203.
7. Nisbet M, Lewenstein B. Biotechnology and the American media: the policy process and the Elite Press, 1970 to 1999. Sci Commun 2002;23:359-391.
8. Bauer M. Public perceptions and mass media in the biotechnology controversy. Int J Public Opin Res 2005;17:5-22.
9. Field A. Discovering statistics using SPSS, 2nd ed. London: Sage Publications, 2005.
10. Cho MK, Illangasekare S, Weaver MA, Leonard DGB, et al. Effects of patents and licenses on the provision of clinical genetic testing services. J Mol Diagn 2003;5:3-8.
11. Walsh T, Casadei S, Coats KH, Swisher E, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006;295:1379-1388.
12. Caulfield T. Policy conflicts: gene patents and health care in Canada. Community Genet 2005;8:223-227.
13. Kitzinger J, Williams C. Forecasting science futures: legitimizing hope and calming fears in the embryo stem cell debate. Soc Sci Med 2005;61:731-740.
14. Highfield R. Selling science to the public. Science 2000;289:59.
15. Nesbit M, Mooney C. Framing science. Science 2007;316:56.
16. Romanow. Building on values: the future of health care in Canada - final report. Saskatoon: Commission on the Future of Health Care in Canada, 2002.
17. Caulfield T, Einsiedel E, Merz J, Nicol D. Trust, patents, and public perceptions: the governance of controversial biotechnology research. Nat Biotechnol 2006;24:1352-1354.
18. Laing A. A report on news media effects and public opinion formation regarding biotechnology issues: a study commissioned by the Canadian Biotechnology Secretariat. Ottawa: Cormex Research, 2004.
19. Nisbet M. The polls - trends: public opinion about stem cell research and human cloning. Public Opin Q 2004;68:131.
20. Government of Canada, Seventh Wave. Public opinion research into biotechnology issues: report prepared for and presented to the Biotechnology Assistant Deputy Minister Coordinating Committee (BACC), Government of Canada. Ottawa: Pollara and Earnscliffe Research and Communications, 2002. Available at: http://www.biostrategy.gc.ca/english/view.asp?x=547&all=true Accessed July 14, 2007.